Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 3 |
Prophylactic vaccine | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein | 1 |
ACE2(Angiotensin-converting enzyme 2) | 1 |
HIV envelope protein gp120 | 1 |
Mechanism HIV envelope protein gp120 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date25 Jul 2022 |
Sponsor / Collaborator |
Start Date14 Mar 2022 |
Sponsor / Collaborator |
Start Date30 Mar 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LC-Plasma-based Vaccine(NIID) | Viral respiratory infection More | Preclinical |
Suvizumab ( HIV envelope protein gp120 ) | HIV Infections More | Preclinical |
JP2024014723 ( SARS-CoV-2 S protein ) | Virus Diseases More | Discovery |
WO2022065445 ( ACE2 ) | Virus Diseases More | Discovery |